Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes

Summary

The purpose of this investigation is to examine the mechanisms mediating vascular dysfunction in women who have had gestational diabetes and how metformin may be a valuable treatment tool to improve microvascular function in these women before the onset of disease.

Eligibility

Inclusion Criteria:

* ≥12 weeks and ≤5 years postpartum
* history of GDM or healthy pregnancy

Exclusion Criteria:

* prediabetes or diabetes (HbA1c ≥5.7%)
* current tobacco use
* cardiovascular or metabolic disease
* cardiovascular or metabolic medication
* history of hypertension during pregnancy
* current pregnancy

Conditions2

Interventions1

Locations1 site

Related trials

• Efficacy of Metformin as an Adjunct to Standard Antidepressant Therapy in Treating Depression Among Obese Patients — Fazaia Ruth Pfau Medical College
• Evaluation of the Chemo-preventive Effect of Combined Topical and Systemic Metformin on Oral Leukoplakia — Cairo University
• Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations — Instituto Nacional de Cancerologia de Mexico
• Metformin as Maintenance Therapy in Patients With Bone Sarcoma and High Risk of Relapse — Istituto Ortopedico Rizzoli
• Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel Function — University of Kansas Medical Center

Browse More Trials